QYUNS-B (02509) Enters into an Exclusive Licensing Agreement with CALDERA THERAPEUTICS for a Preclinical Bispecific Antibody Program Targeting TL1A and IL-17

QYUNS-B (02509) announced that on November 5, 2026, the Company entered into an outbound licensing agreement with Caldera Therapeutics, Inc. for a preclinical-stage bispecific antibody program targeting TL1A and IL-17 (specifically IL-17A and IL-17A/F). Pursuant to the terms and conditions of the licensing agreement, Caldera Therapeutics was granted exclusive, royalty-bearing, transferable and sublicensable rights to research, develop, register, manufacture and commercialize candidate products derived from the licensed program worldwide. In return, the Company or its designated subsidiary will be entitled to receive a one-time, non-refundable and non-creditable upfront payment of US$30 million. Subject to the achievement of certain clinical development, regulatory and commercial milestones, the Group may also receive additional payments of up to US$750 million. During a specified period following the first commercial sale of products derived from the licensed program, the Group will also be entitled to receive tiered royalties on net sales.